Literature DB >> 10807789

Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).

C Touriol1, C Greenland, L Lamant, K Pulford, F Bernard, T Rousset, D Y Mason, G Delsol.   

Abstract

Anaplastic lymphoma kinase (ALK)-positive lymphomas are characterized by expression of a hybrid protein, comprising the cytoplasmic portion of the ALK tyrosine kinase fused to a partner protein. This hybrid kinase is often encoded by the nucleophosmin (NPM) NPM-ALK fusion gene resulting from the (2;5)(p23;q35) chromosomal translocation. However, the ALK gene at 2p23 may also be involved in 2 variant translocations, namely t(1;2)(q25;p23) and t(2;3)(p23;q21), which create the TPM3-ALK and TFG-ALK fusion genes, respectively. We report here 2 lymphomas with an unusual finely granular cytoplasmic ALK staining pattern, clearly different from the pattern observed in ALK-positive lymphomas carrying NPM-ALK or its variants. A cloned complementary DNA sequence from 1 of these 2 lymphomas contained the ALK gene fused to the second clathrin heavy chain gene (also referred to as clathrin heavy polypeptide-like gene) (CLTCL). The distinctive granular cytoplasmic staining pattern for ALK was likely to be due to binding of the fusion protein to clathrin-coated vesicles. The CLTCL gene is constitutively expressed in lymphoid cells and therefore presumably contributes an active promoter for the CLTCL-ALK gene. The fusion protein had a molecular weight (250 kd) that differs from all known ALK products, and it was autophosphorylated in an in vitro kinase assay, confirming that it is constitutively active and hence capable of contributing to malignant transformation. These 2 cases, therefore, represent a hitherto undescribed mechanism of ALK activation in lymphoma and further illustrate the diversity of fusion partners for the ALK gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807789

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.

Authors:  B Maes; V Vanhentenrijk; I Wlodarska; J Cools; B Peeters; P Marynen; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

3.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

4.  Clathrin heavy chain gene fusions expressed in human cancers: analysis of cellular functions.

Authors:  Maria K E Blixt; Stephen J Royle
Journal:  Traffic       Date:  2011-03-24       Impact factor: 6.215

Review 5.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

Review 6.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

7.  Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.

Authors:  Jing Yang; Jun Li; Wei-Yue Gu; Ling Jin; Yan-Long Duan; Shuang Huang; Meng Zhang; Xi-Si Wang; Yi Liu; Chun-Ju Zhou; Chao Gao; Hu-Yong Zheng; Yong-Hong Zhang
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

8.  Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.

Authors:  Xuchao Zhang; Shirley Zhang; Xuening Yang; Jinji Yang; Qing Zhou; Lucy Yin; Shejuan An; Jiaying Lin; Shiliang Chen; Zhi Xie; Mike Zhu; Xiaolin Zhang; Yi-long Wu
Journal:  Mol Cancer       Date:  2010-07-13       Impact factor: 27.401

9.  Anaplastic large-cell lymphoma with atypical chromosomal translocation t(2;5) and hypophyseal tumor.

Authors:  Lei Wang; Yin Tong; Zhimei Chen; Weilai Xu; Jie Jin
Journal:  Ups J Med Sci       Date:  2010-11       Impact factor: 2.384

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.